Početna › Sarkom mekih tkiva › Massachusetts
Kliničke studije za Sarkom mekih tkiva u državi Massachusetts
19 studija za Sarkom mekih tkiva traži sudionike na lokacijama u državi Massachusetts.
Gradovi u državi Massachusetts
Službeni tekst studije (engleski)
Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07059884A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06760819A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
U tijeku regrutacijaFaza 1/2
Do 25 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT04094610Anti-GD2 ADC M3554 in Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT06641908Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT05732831First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT06644755Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT05711615Serial MRI Scans During Radiation Therapy
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT04188535Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention
- Boston Children's Hospital, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacija
Od 15 do 39 godina · Oba spola · Ažurirano 26. kol 2026. · NCT07662239STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT06975293NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Do 30 godina · Oba spola · Ažurirano 3. kol 2026. · NCT06239272Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
- Brigham and Women's Hospital, Boston
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 15. srp 2026. · NCT07377747Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 30. lip 2026. · NCT07675967Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 19 do 110 godina · Oba spola · Ažurirano 29. lip 2026. · NCT02012699A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Massachusetts General Hospital,, Boston
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 27. svi 2026. · NCT03093116Video Education With Result Dependent dIsclosure
- Dana Farber Cancer Institute, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 22. svi 2026. · NCT05225428Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
U tijeku regrutacijaFaza 1/2
Od 12 do 49 godina · Oba spola · Ažurirano 19. velj 2026. · NCT06709495A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 8. lis 2025. · NCT04370587REtroperitoneal SArcoma Registry: an International Prospective Initiative
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 12. velj 2019. · NCT03838718Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.